View in EDS HTML Full Text PDF Full Text

Remisión clínica del asma grave tratada con biológicos en un hospital público de la ciudad de Buenos Aires.

Saved in:
Bibliographic Details
Title: Remisión clínica del asma grave tratada con biológicos en un hospital público de la ciudad de Buenos Aires.
Alternate Title: Clinical remission of severe asthma treated with biologi cal agents in a public hospital in Buenos Aires.
Authors: Saldarini, Fernando1 (AUTHOR) fernando.saldarini@gmail.com, Brichetti, Valeria1 (AUTHOR), Andreu, Mauro2,3 (AUTHOR), Sívori, Martín4 (AUTHOR), Bertozzi, Matías3 (AUTHOR), Guzmán, Cyntia1 (AUTHOR), Rossi, Pamela1 (AUTHOR), Csipka, Paula1 (AUTHOR), Loprete, Lucrecia1 (AUTHOR)
Source: Medicina (Buenos Aires). sep/oct2025, Vol. 85 Issue 5, p960-969. 10p.
Subjects: ASTHMA, DISEASE remission, RETROSPECTIVE studies, MONOCLONAL antibodies, INTERLEUKIN-5, TREATMENT effectiveness, PUBLIC hospitals
Abstract (English): Introduction: Severe asthma affects approximately 5-10% of the asthmatic population and represents a significant burden on healthcare systems. The advent of biological therapies has prompted a redefinition of therapeutic goals, including clinical remission. This study aimed to evaluate the frequency of clinical remission in patients with severe asthma treated with biologic agents. Materials and methods: A retrospective descriptive study was conducted at Hospital Francisco Santojanni. Adult patients with type 2 (T2) severe asthma, according to GINA 2023, who had received biologic treatment for at least 12 months were included. Clinical remission was defined according to GEMA 5.4 and REMAS 2024 crite ria absence of exacerbations, no need for maintenance systemic corticosteroids, Asthma Control Test (ACT) ≥ 20, and FEV1 ≥ 80% of predicted. Clinical, functional, and demographic variables were analyzed before and after treatment. Results: Among 44 patients evaluated, 11 achieved clinical remission. The highest remission rates were observed with anti-IL-5 (7/12) and IL-5R (3/7). In contrast, remission was achieved in only 1 out of 12 patients treated with anti-IgE and in 1 out of 6 treated with anti- IL-4Rα. No significant clinical differences were found between patients who achieved remission and those who did not. Discussion: One in four patients with severe asthma achieved clinical remission with biologic therapy. Agents targeting the IL-5/IL-5R pathway showed greater efficacy. However, the small sample size limits the generaliz ability of the findings. Prospective studies are needed to identify predictors of remission and guide personalized treatment strategies. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Introducción: El asma grave representa entre el 5 y el 10% de la población asmática y constituye una carga para los sistemas de salud. La introducción de terapias biológicas ha impulsado la redefinición de objetivos te rapéuticos, incluyendo la remisión clínica. Este estudio evalúa la frecuencia de remisión clínica en pacientes con asma grave tratados con agentes biológicos. Materiales y métodos: Estudio descriptivo retrospec tivo llevado a cabo en el Hospital Francisco Santojanni. Se incluyeron pacientes con asma grave tipo 2 (T2) según GINA 2023, tratados con biológicos durante al menos 12 meses. La remisión clínica se definió según GEMA 5.4 y REMAS 2024 ausencia de exacerbaciones, sin requerimiento de corticosteroides sistémicos de mantenimiento, test de control de asma (ACT) ≥ 20 y FEV1 ≥ 80% del valor predicho. Se analizaron variables clínicas, funcionales y demográficas antes y después del tratamiento. Resultados: De 44 pacientes evaluados, 11 alcanzaron remisión clínica. La tasa de remisión fue mayor con anti-IL-5, 7 de 12, IL-5R 3 de 7, con anti-IgE 1 de 12 y anti-IL-4Rα 1 de 6. No se observaron diferencias clínicas significativas entre los grupos con y sin remisión. Discusión: Una de cada cuatro personas con asma grave alcanzó remisión clínica con terapia biológica. Los agentes dirigidos a la vía IL-5/IL-5R mostraron mayor eficacia. Sin embargo, los tamaños maestrales reducidos limitan la generalización de los hallazgos. Son necesa rios estudios prospectivos que identifiquen predictores de remisión y orienten el tratamiento personalizado. [ABSTRACT FROM AUTHOR]
Copyright of Medicina (Buenos Aires) is the property of Medicina (Buenos Aires) and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: lth
DbLabel: MedicLatina
An: 189688855
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Remisión clínica del asma grave tratada con biológicos en un hospital público de la ciudad de Buenos Aires.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Clinical remission of severe asthma treated with biologi cal agents in a public hospital in Buenos Aires.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Saldarini%2C+Fernando%22">Saldarini, Fernando</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> fernando.saldarini@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Brichetti%2C+Valeria%22">Brichetti, Valeria</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Andreu%2C+Mauro%22">Andreu, Mauro</searchLink><relatesTo>2,3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sívori%2C+Martín%22">Sívori, Martín</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bertozzi%2C+Matías%22">Bertozzi, Matías</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Guzmán%2C+Cyntia%22">Guzmán, Cyntia</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rossi%2C+Pamela%22">Rossi, Pamela</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Csipka%2C+Paula%22">Csipka, Paula</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Loprete%2C+Lucrecia%22">Loprete, Lucrecia</searchLink><relatesTo>1</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Medicina+%28Buenos+Aires%29%22">Medicina (Buenos Aires)</searchLink>. sep/oct2025, Vol. 85 Issue 5, p960-969. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22ASTHMA%22">ASTHMA</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASE+remission%22">DISEASE remission</searchLink><br /><searchLink fieldCode="DE" term="%22RETROSPECTIVE+studies%22">RETROSPECTIVE studies</searchLink><br /><searchLink fieldCode="DE" term="%22MONOCLONAL+antibodies%22">MONOCLONAL antibodies</searchLink><br /><searchLink fieldCode="DE" term="%22INTERLEUKIN-5%22">INTERLEUKIN-5</searchLink><br /><searchLink fieldCode="DE" term="%22TREATMENT+effectiveness%22">TREATMENT effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22PUBLIC+hospitals%22">PUBLIC hospitals</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Introduction: Severe asthma affects approximately 5-10% of the asthmatic population and represents a significant burden on healthcare systems. The advent of biological therapies has prompted a redefinition of therapeutic goals, including clinical remission. This study aimed to evaluate the frequency of clinical remission in patients with severe asthma treated with biologic agents. Materials and methods: A retrospective descriptive study was conducted at Hospital Francisco Santojanni. Adult patients with type 2 (T2) severe asthma, according to GINA 2023, who had received biologic treatment for at least 12 months were included. Clinical remission was defined according to GEMA 5.4 and REMAS 2024 crite ria absence of exacerbations, no need for maintenance systemic corticosteroids, Asthma Control Test (ACT) ≥ 20, and FEV1 ≥ 80% of predicted. Clinical, functional, and demographic variables were analyzed before and after treatment. Results: Among 44 patients evaluated, 11 achieved clinical remission. The highest remission rates were observed with anti-IL-5 (7/12) and IL-5R (3/7). In contrast, remission was achieved in only 1 out of 12 patients treated with anti-IgE and in 1 out of 6 treated with anti- IL-4Rα. No significant clinical differences were found between patients who achieved remission and those who did not. Discussion: One in four patients with severe asthma achieved clinical remission with biologic therapy. Agents targeting the IL-5/IL-5R pathway showed greater efficacy. However, the small sample size limits the generaliz ability of the findings. Prospective studies are needed to identify predictors of remission and guide personalized treatment strategies. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Introducción: El asma grave representa entre el 5 y el 10% de la población asmática y constituye una carga para los sistemas de salud. La introducción de terapias biológicas ha impulsado la redefinición de objetivos te rapéuticos, incluyendo la remisión clínica. Este estudio evalúa la frecuencia de remisión clínica en pacientes con asma grave tratados con agentes biológicos. Materiales y métodos: Estudio descriptivo retrospec tivo llevado a cabo en el Hospital Francisco Santojanni. Se incluyeron pacientes con asma grave tipo 2 (T2) según GINA 2023, tratados con biológicos durante al menos 12 meses. La remisión clínica se definió según GEMA 5.4 y REMAS 2024 ausencia de exacerbaciones, sin requerimiento de corticosteroides sistémicos de mantenimiento, test de control de asma (ACT) ≥ 20 y FEV1 ≥ 80% del valor predicho. Se analizaron variables clínicas, funcionales y demográficas antes y después del tratamiento. Resultados: De 44 pacientes evaluados, 11 alcanzaron remisión clínica. La tasa de remisión fue mayor con anti-IL-5, 7 de 12, IL-5R 3 de 7, con anti-IgE 1 de 12 y anti-IL-4Rα 1 de 6. No se observaron diferencias clínicas significativas entre los grupos con y sin remisión. Discusión: Una de cada cuatro personas con asma grave alcanzó remisión clínica con terapia biológica. Los agentes dirigidos a la vía IL-5/IL-5R mostraron mayor eficacia. Sin embargo, los tamaños maestrales reducidos limitan la generalización de los hallazgos. Son necesa rios estudios prospectivos que identifiquen predictores de remisión y orienten el tratamiento personalizado. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Medicina (Buenos Aires) is the property of Medicina (Buenos Aires) and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=189688855
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 960
    Subjects:
      – SubjectFull: ASTHMA
        Type: general
      – SubjectFull: DISEASE remission
        Type: general
      – SubjectFull: RETROSPECTIVE studies
        Type: general
      – SubjectFull: MONOCLONAL antibodies
        Type: general
      – SubjectFull: INTERLEUKIN-5
        Type: general
      – SubjectFull: TREATMENT effectiveness
        Type: general
      – SubjectFull: PUBLIC hospitals
        Type: general
    Titles:
      – TitleFull: Remisión clínica del asma grave tratada con biológicos en un hospital público de la ciudad de Buenos Aires.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Saldarini, Fernando
      – PersonEntity:
          Name:
            NameFull: Brichetti, Valeria
      – PersonEntity:
          Name:
            NameFull: Andreu, Mauro
      – PersonEntity:
          Name:
            NameFull: Sívori, Martín
      – PersonEntity:
          Name:
            NameFull: Bertozzi, Matías
      – PersonEntity:
          Name:
            NameFull: Guzmán, Cyntia
      – PersonEntity:
          Name:
            NameFull: Rossi, Pamela
      – PersonEntity:
          Name:
            NameFull: Csipka, Paula
      – PersonEntity:
          Name:
            NameFull: Loprete, Lucrecia
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: sep/oct2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 00257680
          Numbering:
            – Type: volume
              Value: 85
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Medicina (Buenos Aires)
              Type: main
ResultId 1